Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38465961.
- Also identified by DOI 10.1097/RLU.0000000000005137.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who was referred for peptide receptor radionuclide therapy. During intravenous infusion of 7.4 GBq [ 177 Lu]Lu-HA-DOTATATE in the upper right arm, extravasation of the radiopharmaceutical occurred through a displaced intravenous catheter. Planar scintigraphy showed pooling of radioactivity in the right upper arm. After 24 hours, the swelling in the arm was decreased; however, erythema was increased. One week later, symptoms had disappeared, and the patient did not experience any complications during follow-up of 11 months.
Medical subject headings
- Neuroendocrine Tumors
- Organometallic Compounds
- Lutetium
- Radionuclide Imaging
- Positron-Emission Tomography